Cardiovascular outcomes in patients with locally advanced and metastatic prostate cancer treated with luteinising-hormone-releasing-hormone agonists or transdermal oestrogen: the randomised, phase 2 MRC PATCH trial (PR09)

BACKGROUND: Luteinising-hormone-releasing-hormone agonists (LHRHa) to treat prostate cancer are associated with long-term toxic effects, including osteoporosis. Use of parenteral oestrogen could avoid the long-term complications associated with LHRHa and the thromboembolic complications associated w...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Main Authors: Langley, Ruth E, Cafferty, Fay H, Alhasso, Abdulla A, Rosen, Stuart D, Sundaram, Subramanian Kanaga, Freeman, Suzanne C, Pollock, Philip, Jinks, Rachel C, Godsland, Ian F, Kockelbergh, Roger, Clarke, Noel W, Kynaston, Howard G, Parmar, Mahesh KB, Abel, Paul D
Formato: Artigo
Idioma:Inglês
Publicado em: Lancet Pub. Group 2013
Assuntos:
Articles
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC3620898/
https://ncbi.nlm.nih.gov/pubmed/23465742
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/S1470-2045(13)70025-1
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados